NDA 207145/S-005

SUPPLEMENT APPROVAL

US WorldMeds, LLC
Attention: Melissa Bateson
Senior Manager, CMC Regulatory
4441 Springdale Rd
Louisville, KY 40241

Dear Ms. Bateson:

Please refer to your supplemental new drug application (sNDA) dated May 31, 2019, received May 31, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xadago (safinamide) 50 mg and 100 mg Tablets.

This Prior Approval supplemental new drug application provides for the following:

1. To amend the approved Prescribing Information and Patient Prescribing Information pursuant to the Agency's Fulfillment of Postmarketing Requirement and Prior Approval Supplement Request letter dated February 21, 2019, for the following Postmarketing Requirement:

   3184-1 A clinical trial in healthy volunteers to compare the single-dose pharmacokinetics of a Breast Cancer Resistance Protein (BCRP) substrate, either rosuvastatin or sulfasalazine, alone, and after administration of multiple doses of safinamide (100 mg/day).

2. To amend according to the Pregnancy and Lactation Labeling Rule (PLLR) and correct typographical errors not previously identified.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Stacy Metz, PharmD, Senior Regulatory Project Manager, at stacy.metz@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Eric Bastings, MD
Acting Director
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ERIC P BASTINGS
11/25/2019 02:17:46 PM